Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 29, 2023Journal of Atherosclerosis and ThrombosisOpen Access

Association of Antipsychotic Drugs with Venous Thromboembolism: Data Mining of Food and Drug Administration Adverse Event Reporting System and Mendelian Randomization Analysis

View Full Paper
Ask AI
Bookmark
Share

Key result

Antipsychotic drug target gene expression shows no association with VTE risk.

  • OR 1.03
  • 95% CI 0.99-1.07
  • P=0.143
  • n=218,792

Why the study?

Past observational studies reporting on the association between antipsychotics and venous thromboembolism remain controversial, and underlying mechanisms are not fully understood.

Do antipsychotic drugs increase the risk of venous thromboembolism?

Population

Adverse event reports in FAERS and genetic data for Mendelian randomization

Comparison

Antipsychotic drug exposure and drug target gene expression vs non-exposure

Design

FAERS pharmacovigilance data mining and two-sample Mendelian randomization study

Authors

TLTong LiKHKai HuLYLing Ye

Discussion

Loading...

Member takes

Overview

MR finds no causal link to VTE; challenges adverse event signals but leaves open confounding and needs confirmation.

Study Design

Type

Observational (n=218,792)

Structured PICO

Do antipsychotic drugs increase the risk of venous thromboembolism?

P
Population
218,792 European individuals from the FinnGen Biobank analyzed to assess the genetic association between antipsychotic drug target gene expression and venous thromboembolism.
E
Exposure
Antipsychotic drugs (and genetic instruments for their target gene expression)
O
Outcome
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE)safety

Main Result

Odds Ratio: 1.03 (95% CI 0.99–1.07)

p-value: p=0.143

While adverse event databases suggest an association between antipsychotic drugs and VTE, Mendelian randomization fails to provide genetic evidence for a causal relationship.

Limitations

  • Information bias and potential confounding factors in the FAERS database.
  • Absence of expression data for some important target genes like DRD2, DRD3, and HTR2A in the eQTL databases.
  • Removal of some eQTL SNP instruments due to high linkage disequilibrium.
  • Lack of publicly available large GWAS on antipsychotic response to verify the validity of genetic instruments.
  • The specific mechanisms of the pharmacological effects of the identified statistically significant target genes are currently unknown.

Cite This Study

Li et al. (2023) conducted an observational in Venous thromboembolism (n=218,792). Antipsychotic drug target gene expression vs. Unexposed/reference group was evaluated on Venous thromboembolism (VTE) (OR 1.03, 95% CI 0.99-1.07, p=0.143). Mendelian randomization analysis found no significant association between the overall expression of antipsychotic drug target genes in blood and the risk of venous thromboembolism (OR 1.03).

synapsesocial.com/papers/6aa50ca09bfc60db01143298https://doi.org/10.5551/jat.64461
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence2018 · 75 citations
  2. 2Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression2021 · 2,346 citations
  3. 3Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports2001 · 1,825 citations
  4. 4Statistical methods for Mendelian randomization in genome-wide association studies: A review2022 · 305 citations